MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: •  Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/

ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/stocks/GENE60 Degrees Pharmaceuticals (NASDAQ:SXTP): https://www.redchip.com/stocks/SXTPAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations a

ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:60 Degrees Pharmaceuticals (NASDAQ:SXTP): https://www.redchip.com/assets/access/sxtp_accessUnicycive Therapeutics (NASDAQ:UNCY): https://www.redchip.com/assets/access/uncy_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rela

Q3 2024 sales revenue increased 164% year-over-year to $135 thousand.Sequential (quarter-over-quarter) net product revenue growth of 8.3%.Gross profit increased from ($20 thousand) to $24 thousand. WASHINGTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the third fiscal quarter of the 2024 year, ended September 30, 2024. Financial Highlights for the Quarter Ended September 30, 2024: A 140% increase in ARAKODA® pharmacy deliveries from 550 boxes (Q3 2023) to 1,319 boxes (Q3 2024) generated 164% in sa

Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs.ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile. WASHINGTON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company has commenced a nine-month promotional pilot

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement, priced at-the-market under Nasdaq rules, of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warran

WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement p

WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (the "Minimum Bid Price Requirement"), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company had been notified by Nasdaq on February 27, 2024 that it was not in compliance with the Minimum Bid

Q2 2024 net product revenues doubled year-over-year to $125 thousandSequential (quarter-over-quarter) net product revenue growth of 18.3%Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended June 30, 2024. Financial Highlights: 110% net product revenue growth resulted from an increase in ARAKODA® pharmacy deliveries of 288%, from 331 boxes (Q2 2023) to 1,301 boxes (Q2 2024).The Company ac

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria.SJ733 will be combined with a single dose of tafenoquine in the study.The right of reference allows FDA to review 60 Degrees Pharma's regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has granted the University of Kentucky a right of reference to the Compan

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split ("Reverse Stock Split") of its common stock, par value $0.0001 per share ("Common Stock"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SXTP" and will begin trading on a split-adjusted basis when the market opens on August 12, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 83006G203. The Reverse Stock Split is primarily intended

60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA® (tafenoquine), the Company's FDA-approved product indicated for malaria preventionAnticipating increasing ARAKODA sales volume in 2024, the Company increased the commercial batch size of ARAKODA in Q1 2024Q1 2024 ARAKODA sales revenue increased 515% year-over-year to $105.7 thousand WASHINGTON, July 25, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious d

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical CenterPatient enrollment has begun; interim results anticipated by September, 2025In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tick-borne, potentially life-threatening illnessCase studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failedTotal cumulative accessible market through the end of patent protection in the U.S. for ARAKODA® (tafe

10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

DEF 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

PRE 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

EFFECT - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

S-3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded down 0.91% to 40,293.66 while the NASDAQ fell 0.70% to 17,746.27. The S&P 500 also fell, dropping, 0.61% to 5,510.84. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsHeath care shares jumped by 0.5% on Thursday. In trading on Thursday, information technology shares fell by 1%. Top Headline Netflix Inc. (NASDAQ:NFLX) posted better-than-expected earnings and sales results for its second quarter, after the closing bell on Thursday. The company ende

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) shares are surging on Friday following the company’s announcement of clinical trial agreements for their Tafenoquine Babesiosis study. What Happened: The company has signed clinical trial agreements with Yale University, Rhode Island Hospital and Tufts Medical Center. This marks the world’s first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. Patient enrollment has commenced and interim results are expected by September 2025. Babesiosis, an emerging tick-borne disease in the Northeast U.S., can be life-threatening, especially in elderly and

Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points on Friday. The Dow traded down 0.78% to 40,347.51 while the NASDAQ fell 0.29% to 17,819.43. The S&P 500 also fell, dropping, 0.29% to 5,528.67. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsCommunication services shares jumped by 0.7% on Thursday. In trading on Thursday, materials shares fell by 1%. Top Headline Schlumberger N.V. (NYSE:SLB) reported better-than-expected second-quarter results. The company said revenue increased 13% year-over-year to $9.139 billion, beating

U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.32% to 40,532.98 while the NASDAQ rose 0.14% to 17,895.95. The S&P 500 also rose, gaining, 0.17% to 5,553.92. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Real Estate Stocks Delivering High-Dividend Yields Leading and Lagging SectorsCommunication services shares jumped by 1% on Thursday. In trading on Thursday, energy shares fell by 0.6%. Top Headline American Express Co (NYSE:AXP) reported better-than-expected earnings for its second quarter on Friday. The company's second-quarter revenue

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tick-borne, potentially life-threatening illnessCase studies in recent medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failedTotal cumulative accessible market through the end of patent protection in the U.S. for ARAKODA® (taf

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results. Intuitive Surgical reported second-quarter revenue of $2.01 billion, beating the consensus estimate of $1.97 billion. The robotic-assisted surgery company reported quarterly adjusted earnings of $1.78 per share, beating analyst estimates of $1.54 per share. Intuitive Surgical shares jumped 6.7% to $444.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Serve Robotics Inc. (NASDAQ:SERV) gained 68.4% to $4.43 in pre-market trading after gaining over 12% on Thursday.

SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)